Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commentary: From boardroom to courtroom: maximising your return - by Hitesh Patel and Simon tottman of KPMG

This article was originally published in Scrip

Executive Summary

Pharmaceutical companies are revising their operating models in order to reduce costs and take advantage of fresh opportunities. For example, outsourcing to lower cost jurisdictions and joint-venture developments to manage the risk of large R&D investments.

Topics

UsernamePublicRestriction

Register

SC005892

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel